Negative / Null Result ReportMedicine
Guckenberger M, Opitz I, Dellaporta T et al. · 2025 · Lung cancer (Amsterdam, Netherlands)
Objective To evaluate the addition of immunotherapy and metastasis-directed stereotactic body radiotherapy (SBRT) to induction chemotherapy followed by definitive local therapy of the locoregional primary tumour in patients with…
View details →Negative / Null Result ReportMedicine
Lee JB, Choi SJ, Shim HS et al. · 2025 · Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Introduction Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB to IIIA NSCLC harboring EGFR mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated…
View details →Negative / Null Result ReportOpen accessMedicine
Wills CA, Mohan S, Nabavizadeh A et al. · 2025 · Neuro-oncology advances
Background Novel treatments are needed for oligodendroglioma that has recurred following radiotherapy (RT) and chemotherapy. The cyclin D1-CDK4 axis is frequently dysregulated in oligodendroglioma. Abemaciclib is a selective CDK4/6…
View details →Negative / Null Result ReportOpen accessMedicine
Cheng S, Kordbacheh T, Banyard A et al. · 2026 · Oncology research
Objectives The PACIFIC trial established the benefit of durvalumab following chemo-radiotherapy for stage III non-small cell lung cancer (NSCLC). However, the concurrent use of radiotherapy (RT) and durvalumab (PACIFIC-2 trial) showed no…
View details →Negative / Null Result ReportMedicine
Kaufman MR, Goldman HB, Chermansky CJ et al. · 2024 · Neurourology and urodynamics
Aims This study aimed to determine the efficacy and safety of iltamiocel investigational autologous muscle cell therapy in females with stress urinary incontinence (SUI). Methods Adult females were randomized 2:1 to iltamiocel (150 × 10 6…
View details →Negative / Null Result ReportMedicine
Shiraishi Y, Shimose T, Tobino K et al. · 2025 · Lung cancer (Amsterdam, Netherlands)
Background The current standard of care for advanced non-small cell lung cancer (NSCLC) without driver oncogenes is platinum-based chemotherapy together with immune checkpoint inhibition. However, most phase 3 trials of such combination…
View details →Negative / Null Result ReportOpen accessMedicine
Lan H, Lu M, Li S et al. · 2026 · Frontiers in medicine
Objective High-quality bowel preparation is essential for accurate colonoscopy. Currently, linaclotide is used as an adjunctive agent supporting bowel preparation, but evidence for its combination with oral sulfate solution (OSS) remains…
View details →Negative / Null Result ReportMedicine
Damas OM, Leo M, Colina N et al. · 2025 · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Background & aims Diet may influence ulcerative colitis (UC), but its impact on medication response remains unclear. We examined whether two 5-day cycles of a low-calorie, plant-based (LC-PB), fasting-mimicking diet could improve UC…
View details →Negative / Null Result ReportOpen accessMedicine
Masuishi T, Taniguchi H, Kotani D et al. · 2025 · ESMO open
Background Based on the reported antitumor effects of microtubule inhibitors in xenograft models of BRAF V600E mutant colorectal cancer, this multicenter phase II study aimed to evaluate the efficacy and safety of eribulin in patients with…
View details →Negative / Null Result ReportOpen accessMedicine
Crown J, Eustace AJ, Collins DM et al. · 2025 · Acta oncologica (Stockholm, Sweden)
Background The docetaxel (T), carboplatin (C) and trastuzumab (H) regimen has been used in the (neo-) adjuvant treatment of HER2+ early stage breast cancer (ESBC). Lapatinib (L) a small molecule HER2 antagonist produces clinical responses…
View details →Negative / Null Result ReportMedicine
Zhang X, Yan J, Lei Q et al. · 2025 · International journal of radiation oncology, biology, physics
Purpose To investigate the efficacy of metastasis-directed therapy (MDT) when added to camrelizumab (Cam) in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). Methods and materials We conducted a randomized,…
View details →Negative / Null Result ReportMedicine
Rhee H, Henderson LM, Bauer RN et al. · 2024 · Allergy
Background Tryptase, a mast cell protease, has been identified as a potential therapeutic target in managing patients with refractory asthma. We assessed the efficacy, safety, pharmacokinetics, and pharmacodynamics of MTPS9579A, an…
View details →Negative / Null Result ReportMedicine
Yoshioka H, Ishida T, Atagi S et al. · 2025 · Clinical lung cancer
Background We conducted a randomize phase II study to evaluate the efficacy and safety of topoisomerase II inhibitor amrubicin plus topoisomerase I inhibitor irinotecan (AI) compared with cisplatin plus irinotecan (PI) as first-line…
View details →Negative / Null Result ReportMedicine
Pressiani T, Balsano R, Giordano L et al. · 2024 · European journal of cancer (Oxford, England : 1990)
Introduction The prognosis of patients with advanced biliary tract cancer (BTC) is still poor, and new strategies improving patients' outcome are needed. In our trial we investigated safety and activity of nab-paclitaxel in combination…
View details →Failed Experiment ReportOpen accessMedicine
Cree BAC, Freedman MS, Gold M et al. · 2025 · Annals of neurology
Objective Elezanumab is a monoclonal antibody that binds repulsive guidance molecule a (RGMa), an inhibitor of central nervous system regeneration after inflammation or injury. The aim was to assess the safety and efficacy of elezanumab in…
View details →Failed Experiment ReportMedicine
Lee JM, Miller A, Rose PG et al. · 2025 · Clinical cancer research : an official journal of the American Association for Cancer Research
Purpose We assessed the efficacy of anti-PD-L1 durvalumab in combination with olaparib and cediranib (DOC), compared with the standard-of-care chemotherapy (SOC) in patients with platinum-resistant ovarian cancer (PROC), who had prior…
View details →Negative / Null Result ReportMedicine
Gong J, Mita AC, Wei Z et al. · 2024 · JCO precision oncology
Purpose Despite fibroblast growth factor receptor ( FGFR ) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies.…
View details →Negative / Null Result ReportOpen accessMedicine
King B, Mesinkovska N, Senna M et al. · 2025 · Journal of the European Academy of Dermatology and Venereology : JEADV
Background Etrasimod, an oral, selective sphingosine 1-phosphate 1, 4 and 5 receptor modulator approved for the treatment of ulcerative colitis, has been studied in immune-mediated inflammatory diseases, including alopecia areata (AA).…
View details →Negative / Null Result ReportMedicine
Schulte B, Mohindra N, Milhem M et al. · 2021 · British journal of cancer
Background Pazopanib is active in refractory soft-tissue sarcoma (STS) and significantly prolongs PFS. Prior studies of combinations of metronomic topotecan with pazopanib have indicated preclinical evidence of response in patients with…
View details →Negative / Null Result ReportOpen accessMedicine
Thavaneswaran S, Lin F, Espinoza D et al. · 2025 · NPJ precision oncology
This single-arm phase II trial (ACTRN12620000918921) evaluated the clinical activity of tremelimumab (10 mg/kg intravenously every 4 weeks for 6 cycles) in advanced cancers with a high tumour mutational burden (TMB), defined as TMB > 10…
View details →Negative / Null Result ReportOpen accessMedicine
Hsu YC, Lin PT, Teng W et al. · 2024 · Cancers
Background The combination of anti-angiogenic therapy and immune checkpoint inhibitors has revolutionized the management of unresectable hepatocellular carcinoma (uHCC). While an early-phase study demonstrated promising outcomes for…
View details →Negative / Null Result ReportMedicine
Harada H, Omori S, Mori K et al. · 2022 · International journal of clinical oncology
Background This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced non-small cell lung cancer (NSCLC). Methods The major inclusion criteria were…
View details →Failed Experiment ReportMedicine
Andres S, Finch L, Iasonos A et al. · 2024 · Gynecologic oncology
Objective To determine the safety and efficacy of the oral progesterone antagonist onapristone extended release (onapristone-XR) in patients with recurrent progesterone receptor (PR)-positive adult-type granulosa cell tumor (aGCT),…
View details →Replication FailureOpen accessMedicine
Takagi K, Saito G, Tanaka H et al. · 2025 · ESMO open
Background The REMORA trial demonstrated efficacy and safety of lenvatinib in patients previously treated for advanced thymic carcinoma. However, more data regarding its use in clinical practice are required. Methods This multicenter…
View details →Negative / Null Result ReportMedicine
Kerwin E, Dorinsky P, Patel M et al. · 2022 · The Journal of asthma : official journal of the Association for the Care of Asthma
Objective To evaluate the efficacy and safety of three doses of glycopyrrolate metered dose inhaler (GP MDI) in patients with uncontrolled asthma despite treatment with inhaled corticosteroid/long-acting β 2 -agonists (ICS/LABA) with or…
View details →Negative / Null Result ReportOpen accessMedicine
Kirschner P, Konen FF, Axhausen F et al. · 2026 · Therapeutic advances in neurological disorders
Background B-cell depleting therapies (BCDT), including ocrelizumab, ofatumumab, and ublituximab, are highly effective disease-modifying therapies for multiple sclerosis (MS). Several case reports have raised concerns about new-onset or…
View details →Negative / Null Result ReportMedicine
Lumish M, Chui MH, Zhou Q et al. · 2024 · Gynecologic oncology
Objective HER2 overexpression is associated with decreased overall survival in metastatic endometrial cancer. Trastuzumab with chemotherapy has demonstrated efficacy for first-line management of advanced HER2+ endometrial carcinoma, but…
View details →Negative / Null Result ReportOpen accessMedicine
Cecchini M, Kwiek B, Liu-Walsh F et al. · 2026 · Dermatology and therapy
Introduction Atopic dermatitis (AD) is a chronic, inflammatory skin disease with a high burden and unmet needs. Herein, we have assessed the efficacy and safety of JNJ-67484703, a programmed cell death protein 1 (PD-1)-agonizing/depleting…
View details →Negative / Null Result ReportOpen accessMedicine
Chang JY, Balch C, Oh HS · 2024 · Viruses
Herpes simplex virus (HSV) has coevolved with Homo sapiens for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or…
View details →Negative / Null Result ReportMedicine
Sabha M, Siaton BC, Hochberg MC · 2020 · Expert opinion on investigational drugs
Introduction : Osteoarthritis (OA) is the most common form of arthritis. Knee OA is associated with joint pain, activity limitation, physical disability, reduced health-related quality of life, and increased mortality. To date, all…
View details →